Viatris Inc. reported third-quarter 2026 total revenues of $3.75 billion, essentially flat year-over-year on an operational basis. The company posted a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion, up 4% from the prior year period. Management raised the midpoint of its full-year 2026 financial guidance for all key metrics, including adjusting the adjusted EBITDA midpoint to $4.5 billion and adjusted EPS to $2.60. The firm also announced regulatory approvals for RYZUMVI in the U.S. and WAKIX in Japan, and confirmed it has returned approximately $717 million of capital to shareholders year-to-date through share repurchases. Viatris operates as a global healthcare company providing generics, value-added medicines, established brands, and innovative medicines.
